RA Capital Management CCCC Position
Exited4-Fund ConvergenceRA Capital Management exited their position in C4 Therapeutics Inc. (CCCC) in Q1 2024, after holding the stock for 2 quarters.
The position was first reported in Q4 2023 and has been tracked across 2 quarterly 13F filings.
CCCC is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Cemsidomide in 1447 days (Mar 31, 2030), making the timing of RA Capital's position particularly relevant.
Short interest stands at 14.7% of float with 4.2 days to cover, indicating significant bearish positioning against the stock.
About C4 Therapeutics Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Full company profile →Short Interest
14.7%
4.2 days to cover
RA Capital Management CCCC Position History
Frequently Asked Questions
Does RA Capital Management own CCCC?
No. RA Capital Management exited their position in C4 Therapeutics Inc. (CCCC) in Q1 2024. They previously held the stock for 2 quarters.
How many hedge funds own CCCC?
4 specialist biotech hedge funds currently hold CCCC, including Commodore Capital, OrbiMed Advisors, Tang Capital Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy CCCC?
RA Capital Management's position in CCCC was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's CCCC position increasing or decreasing?
RA Capital Management completely exited their CCCC position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CCCCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →